Amélie Darlix

20PUBLICATIONS
56CO-AUTHORS
Molecular targetsPredictive and prognostic markersPacific Peoples midwifery and paediatricsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Sep 17, 2026
Multidisciplinary recommendations for routine follow-up of isocitrate dehydrogenase‑mutant glioma in 2026: Adapting clinical practice to the molecular era.

|Aug 12, 2026
Modeling tumor volume trajectory and outcome identifies 3 distinct response classes in lower-grade IDH-mutant glioma receiving first-line chemotherapy.

|Feb 16, 2026
Beyond proof-of-concept: Validating robust automated diffuse lower-grade glioma segmentation for clinical applications in longitudinal follow-up.

Jeremy Deverdun, Guillaume Clain, Margaux Verdier

|May 12, 2025
Integrated early palliative care for patients with newly diagnosed glioblastoma: The GLIOSUPPORT feasibility study.

Michel Fabbro, Muriel Thomaso, Amélie Darlix

|Jan 08, 2025
Who will benefit from vorasidenib? Review of data from the literature and open questions.

Amélie Darlix, Matthias Preusser, Shawn L Hervey-Jumper

|Aug 02, 2024
Descriptive epidemiology of 399 histologically confirmed newly diagnosed meningeal solitary fibrous tumours and haemangiopericytomas in France: 2006-2015.

Charles Champeaux Depond, Sonia Zouaoui, Amélie Darlix

Pageof 4

Frequent Collaborators

4 joint publications

Estelle Guerdoux-Ninot

4 joint publications

Luc Bauchet

4 joint publications

Valérie Rigau

3 joint publications

Hugues Duffau